Keyword: Janssen Biotech

Innovation challenges continue to grow, but don't worry about brain drain. There are plenty of ideas still to go around.

Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.

Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.

Pushing to eradicate hepatitis C in England, the NHS is weighing bids for bulk drug buys, but AbbVie has sued over an unfair bidding process.

Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.

With Pancreaze, a drug for CF patients, Vivus is stepping into an unfamiliar market. So it sponsored a fundraising event to get its name out.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

At last year’s ESC meeting, J&J was touting data that put its clot-busting Xarelto on track for $1 billion-plus in additional sales. Not so this year.

Months ahead of the FDA decision date, the agency approved AbbVie and J&J's Imbruvica, plus Roche's Rituxan, to treat adults with a rare blood cancer.

Healthcare reporters questioned a Johnson & Johnson TV ad for anticoagulant treatment Xarelto, calling out potentially "misleading" visuals.